Nof Corporation

National Institute of Infectious Diseases

Saitama Medical University

Hokkaido University

Maiko Taneichi

Tetsuya Uchida

Shoichi Yokoyama

Masanori Matsui

Hiroshi Oda

Toshitaka Akatsuka

Ai Mikuma

Kiichi Kajino

The invention provides a method for the prophylaxis or treatment of hepatitis C in a mammal with a peptide-bound liposome wherein the peptide contains a partial amino acid sequence having a length of not less than 9 amino acids in the amino acid sequence of hepatitis C virus NS3 protein, has a length of 9 to 11 amino acids, and is capable of inducing cytotoxic T lymphocytes; the liposome contains a phospholipid containing an acyl group having 14 to 24 carbon atoms and one unsaturated bond or a hydrocarbon group having 14 to 24 carbon atoms and one unsaturated bond, and a liposome stabilizer; and the peptide is bound to the surface of the liposome. The invention also provides a cytotoxic T lymphocyte activator containing the peptide-bound liposome, as well as a hepatitis C virus vaccine.

Hepatitis C virus liposome vaccine

The present invention provides an avian influenza vaccine containing a peptide-bound liposome wherein; the peptide contains:

Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain

Growing community of inventors

Tokyo, Japan

Maiko Taneichi